Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of F901318 IR Tablet in Healthy Volunteers
NCT02808741Phase 1Completed
- Sponsor
- F2G
- Start
- Jul 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of olorofim in invasive aspergillosis (IA) (6 arms), sponsored by F2G. Primary endpoint: Pharmacokinetics at 120 hours. Started Jul 2016; status: completed.
02
Drugs
olorofim
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on NCT02808741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02808741.